Abstract

Vitamin D, for many years after the discovery, primarily was associated with bone metabolic processes. Currently, many studies indicate its beneficial effect in the prevention and treatment of many diseases, including cancer. However, deficiency of vitamin D is associated with greater tendency to get sick and worse prognosis in treatment, especially cancer. Calcitriol, an active form of vitamin D (1.25(OH)2D3) and its analogues have a pleiotropic activity, including anti-cancer properties. Many studies indicate, that the active forms of vitamin D3 may show anti-proliferative effects in cancer cells by inhibiting the cell cycle, inducing differentiation or leading to apoptosis and enhancing autophagy. Also, extremely important are the possibilities of reducing the invasiveness of tumours through the influence on angiogenesis or adhesion and others. Especially, the anti-cancer role of vitamin D3 is suggested in the case of tumors whose cells express VDR receptors. Interestingly, many cancer cells not only express the VDR receptors, but also due to the expression of CYP27B1 and CYP24A hydroxylases, they can regulate metabolism of calcitriol. Many of the studies using vitamin D3 show that calcitriol and its analogues, due to the influence on cancer cells, can play promising roles in anticancer therapies. Consider the broad pleiotropism of the action of active metabolites of vitamin D3 and the development of research in this field, the current work presents the effect of active forms of vitamin D on some signalling pathways and the regulation of selected proteins in various cancers.

References

• 1. Aguilera O., Pena C., Garcia J.M., Larriba M.J., Ordonez-Moran P.,Navarro D., Barbachano A., Lopez de Silanes I., Ballestar E., FragaM.F., Esteller M., Gamallo C., Bonilla F., Gonzalez-Sancho J.M., MunozA.: The Wnt antagonist DICKKOPF-1 gene is induced by 1α,25-dihydroxyvitamin D3 associated to the differentiation of humancolon cancer cells. Carcinogenesis, 2007; 28: 1877–1884
  Google Scholar
• 2. Anderson M.G., Nakane M., Ruan X., Kroeger P.E., Wu-Wong J.R.:Expression of VDR and CYP24A1 mRNA in human tumors. CancerChemother. Pharmacol., 2006; 57: 234–240
  Google Scholar
• 3. Annalora A.J., Goodin D.B., Hong W.X., Zhang Q., Johnson E.F., StoutC.D.: Crystal structure of CYP24A1, a mitochondrial cytochrome P450involved in Vitamin D metabolism. J. Mol. Biol., 2010; 396: 441–451
  Google Scholar
• 4. Artaza J.N., Sirad F., Ferrini M.G., Norris K.C.: 1,25(OH)2vitaminD3 inhibits cell proliferation by promoting cell cycle arrest withoutinducing apoptosis and modifies cell morphology of mesenchymalmultipotent cells. J. Steroid Biochem. Mol. Biol., 2010; 119: 73–83
  Google Scholar
• 5. Autier P., Gandini S.: Vitamin D supplementation and total mortality:a meta-analysis of randomized controlled trials. Arch. Intern.Med., 2007; 167: 1730–1737
  Google Scholar
• 6. Avila E., García-Becerra R., Rodríguez-Rasgado J.A., Díaz L., Ordaz-Rosado D., Zügel U., Steinmeyer A., Barrera D., Halhali A., LarreaF., Camacho J.: Calcitriol down-regulates human ether à go-go 1potassium channel expression in cervical cancer cells. AnticancerRes., 2010; 30: 2667–2672
  Google Scholar
• 7. Banakar M.C., Paramasivan S.K., Chattopadhyay M.B., Datta S., ChakrabortyP., Chatterjee M., Kannan K., Thygarajan E.: 1α, 25-dihydroxyvitaminD3 prevents DNA damage and restores antioxidant enzymesin rat hepatocarcinogenesis induced by diethylnitrosamine and promotedby phenobarbital. World J. Gastroenterol., 2004; 10: 1268–1275
  Google Scholar
• 8. Bao B.Y., Ting H.J., Hsu J.W., Lee Y.F.: Protective role of 1α, 25-dihydroxyvitaminD3 against oxidative stress in nonmalignant humanprostate epithelial cells. Int. J. Cancer, 2008; 122: 2699–2706
  Google Scholar
• 9. Bao B.Y., Yao J., Lee Y.F.: 1α, 25-dihydroxyvitamin D3 suppressesinterleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis,2006; 27: 1883–1893
  Google Scholar
• 10. Bao Y., Ng K., Wolpin B.M., Michaud D.S., Giovannucci E., FuchsC.S.: Predicted vitamin D status and pancreatic cancer risk in twoprospective cohort studies. Br. J. Cancer, 2010; 102: 1422–1427
  Google Scholar
• 11. Bareis P., Bises G., Bischof M.G., Cross H.S., Peterlik M.: 25-Hydroxy-vitamin D metabolism in human colon cancer cells during tumorprogression. Biochem. Biophys. Res. Commun., 2001; 285: 1012–1017
  Google Scholar
• 12. Berlanga-Taylor A.J., Knight J.C.: An integrated approach to defininggenetic and environmental determinants for major clinicaloutcomes involving vitamin D. Mol. Diagn. Ther., 2014; 18: 261–272
  Google Scholar
• 13. Bertone-Johnson E.R., Chen W.Y., Holick M.F., Hollis B.W., ColditzG.A., Willett W.C., Hankinson S.E.: Plasma 25-hydroxyvitamin D and1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol.Biomarkers Prev., 2005; 14: 1991–1997
  Google Scholar
• 14. Bessler H., Djaldetti M.: 1α,25-dihydroxyvitamin D3 modulatesthe interaction between immune and colon cancer cells. Biomed.Pharmacother., 2012; 66: 428–432
  Google Scholar
• 15. Bikle D.D.: Vitamin D metabolism, mechanism of action, andclinical applications. Chem. Biol., 2014; 21: 319–329
  Google Scholar
• 16. Bikle D.D., Elalieh H., Welsh J., Oh D., Cleaver J., Teichert A.:Protective role of vitamin D signaling in skin cancer formation. J.Steroid Biochem. Mol. Biol., 2013; 136: 271–279
  Google Scholar
• 17. Brożyna A.A., Jóźwicki W., Janjetovic Z., Slominski A.T.: Expressionof the vitamin D–activating enzyme 1α-hydroxylase (CYP27B1) decreasesduring melanoma progression. Hum. Pathol., 2013; 44: 374–387
  Google Scholar
• 18. Brożyna A.A., Józwicki W., Jochymski C., Slominski A.T.: Decreasedexpression of CYP27B1 correlates with the increased aggressivenessof ovarian carcinomas. Oncol. Rep., 2015; 33: 599–606
  Google Scholar
• 19. Brożyna A.A., Jóźwicki W., Slominski A.T.: Decreased VDR expressionin cutaneous melanomas as marker of tumor progression: Newdata and analyses. Anticancer Res., 2014; 34: 2735–2744
  Google Scholar
• 20. Burns E.M., Elmets C.A., Yusuf N.: Vitamin D and skin cancer.Photochem. Photobiol., 2015; 91: 201–209
  Google Scholar
• 21. Buttigliero C., Monagheddu C., Petroni P., Saini A., Dogliotti L.,Ciccone G., Berruti A.: Prognostic role of vitamin D status and efficacyof vitamin D supplementation in cancer patients: A systematicreview. Oncologist, 2011; 16: 1215–1227
  Google Scholar
• 22. Caligo M.A., Cipollini G., Petrini M., Valentini P., Bevilacqua G.:Down regulation of NM23.H1, NM23.H2 and c-myc genes duringdifferentiation induced by 1,25 dihydroxyvitamin D3. Leuk. Res.,1996; 20: 161–167
  Google Scholar
• 23. Cazares-Ordonez V., Gonzalez-Duarte R.J., Diaz L., Ishizawa M.,Uno S., Ortiz V., Ordonez-Sanchez M.L., Makishima M., Larrea F.,Avila E.: A cis-acting element in the promoter of human ether a go–go 1 potassium channel gene mediates repression by calcitriol inhuman cervical cancer cells. Biochem. Cell Biol., 2015; 93: 94–101
  Google Scholar
• 24. Chen T.C., Holick M.F.: Vitamin D and prostate cancer preventionand treatment. Trends Endocrinol. Metab., 2003; 14: 423–430
  Google Scholar
• 25. Chen Y., Zhang J., Ge X., Du J., Deb D.K., Li Y.C.: Vitamin D receptorinhibits nuclear factor κB activation by interacting with IκBkinase β protein. J. Biol. Chem., 2013; 288: 19450–19458
  Google Scholar
• 26. Christakos S., Dhawan P., Verstuyf A., Verlinden L., CarmelietG.: Vitamin D: Metabolism, molecular mechanism of action, andpleiotropic effects. Physiol. Rev., 2016; 96: 365–408
  Google Scholar
• 27. Colston K., Colston M.J., Feldman D.: 1,25-dihydroxevitamin D3and malignant melanoma: the presence of receptors and inhibitionof cell growth in culture. Endocrinology, 1981; 108: 1083–1086
  Google Scholar
• 28. Colston K.W., James S.Y., Ofori-Kuragu E.A., Binderup L., GrantA.G.: Vitamin D receptors and anti-proliferative effects of vitaminD derivatives in human pancreatic carcinoma cells in vivo and invitro. Br. J. Cancer, 1997; 76: 1017–1020
  Google Scholar
• 29. Deeb K.K., Trump D.L., Johnson C.S.: Vitamin D signalling pathwaysin cancer: Potential for anticancer therapeutics. Nat. Rev.Cancer, 2007; 7: 684–700
  Google Scholar
• 30. Díaz L., Díaz-Muñoz M., García-Gaytán A.C., Méndez I.: Mechanisticeffects of calcitriol in cancer biology. Nutrients, 2015; 7: 5020–5050
  Google Scholar
• 31. Didonato J.A., Mercurio F., Karin M.: NF-kB and the link betweeninflammation and cancer. Immunol. Rev., 2012; 246: 379–400
  Google Scholar
• 32. Doroudi M., Schwartz Z., Boyan B.D.: Phospholipase A2 activatingprotein is required for 1α,25-dihydroxyvitamin D3 dependentrapid activation of protein kinase C via Pdia3. J. Steroid Biochem.Mol. Biol., 2012; 132: 48–56
  Google Scholar
• 33. Ferrer-Mayorga G., Larriba M.J., Crespo P., Muñoz A.: Mechanismsof action of vitamin D in colon cancer. J. Steroid Biochem. Mol.Biol., 2019; 185: 1–6
  Google Scholar
• 34. Field S., Elliott F., Randerson-Moor J., Kukalizch K., Barrett J.H.,Bishop D.T., Newton-Bishop J.A.: Do vitamin A serum levels moderateoutcome or the protective effect of vitamin D on outcome frommalignant melanoma? Clin. Nutr., 2013; 32: 1012–1016
  Google Scholar
• 35. Fleet J.C.: Molecular actions of vitamin D contributing to cancerprevention. Mol. Aspects Med., 2008; 29: 388-396
  Google Scholar
• 36. Fleet J.C., DeSmet M., Johnson R., Li Y.: Vitamin D and cancer:a review of molecular mechanisms. Biochem. J., 2012; 441: 61–76
  Google Scholar
• 37. García-Becerra R., Díaz L., Camacho J., Barrera D., Ordaz-RosadoD., Morales A., Ortiz C.S., Avila E., Bargallo E., Arrecillas M., HalhaliA., Larrea F.: Calcitriol inhibits ether-à go-go potassium channelexpression and cell proliferation in human breast cancer cells. Exp.Cell Res., 2010; 316: 433–442
  Google Scholar
• 38. García-Quiroz J., García-Becerra R., Santos-Martínez N., BarreraD., Ordaz-Rosado D., Avila E., Halhali A., Villanueva O., Ibarra-SánchezM.J., Esparza-López J., Gamboa-Domínguez A., Camacho J., Larrea F.,Díaz L.: In vivo dual targeting of the oncogenic ether-à-go-go-1 potassiumchannel by calcitriol and astemizole results in enhanced antineoplasticeffects in breast tumors. BMC Cancer, 2014; 14: 745–754
  Google Scholar
• 39. Garland C.F., Gorham E.D., Mohr S.B., Grant W.B., GiovannucciE.L., Lipkin M., Newmark H., Holick M.F., Garland F.C.: Vitamin D andprevention of breast cancer: Pooled analysis. J. Steroid Biochem. Mol.Biol., 2007; 103: 708–711
  Google Scholar
• 40. Goodwin P.J., Ennis M., Pritchard K.I., Koo J., Hood N.: Prognosticeffects of 25-hydroxyvitamin D levels in early breast cancer. J. Clin.Oncol., 2009; 27: 3757–3763
  Google Scholar
• 41. Gorham E.D., Garland C.F., Garland F.C., Grant W.B., Mohr S.B.,Lipkin M., Newmark H.L., Giovannucci E., Wei M., Holick M.F.: VitaminD and prevention of colorectal cancer. J. Steroid Biochem. Mol.Biol., 2005; 97: 179–194
  Google Scholar
• 42. Guzey M., Kitada S., Reed J.C.: Apoptosis induction by 1α,25-dihydroxyvitamin D3 in prostate cancer. Mol. Cancer Ther., 2002;1: 667–677
  Google Scholar
• 43. Hager G., Kornfehl J., Knerer B., Weigel G., Formanek M.: Molecularanalysis of p21 promoter activity isolated from squamous carcinomacell lines of the head and neck under the influence of 1,25(OH)2vitamin D3 and its analogs. Acta Otolaryngol., 2004; 124: 90–96
  Google Scholar
• 44. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., ThompsonP.D., Selznick S.H., Dominguez C.E., Jurutka P.W.: The nuclearvitamin D receptor: Biological and molecular regulatory propertiesrevealed. J. Bone Miner. Res., 1998; 13: 325–349
  Google Scholar
• 45. Henry H.L.: Regulation of vitamin D metabolism. Best Pract. Res.Clin. Endocrinol. Metab., 2011; 25: 531–541
  Google Scholar
• 46. Hmama Z., Nandan D., Sly L., Knutson K.L., Herrera-Velit P.,Reiner N.E.: 1α,25-Dihydroxyvitamin D3-induced myeloid cell differentiationis regulated by a vitamin D receptor-phosphatidylinositol3-kinase signaling complex. J. Exp. Med., 1999; 190: 1583–1594
  Google Scholar
• 47. Holick M.F.: Vitamin D: A millenium perspective. J. Cell. Biochem.,2003; 88: 296–307
  Google Scholar
• 48. Holick M.F.: Vitamin D deficiency. N. Engl. J. Med., 2007; 357: 266–281
  Google Scholar
• 49. Hossein-Nezhad A., Holick M.F.: Vitamin D for health: A globalperspective. Mayo Clin. Proc., 2013; 88: 720–755
  Google Scholar
• 50. Huynh H., Pollak M., Zhang J.C.: Regulation of insulin-like growthfactor (IGF) II and IGF binding protein 3 autocrine loop in humanPC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 andits analog EB1089. Int. J. Oncol., 1998; 13: 137–143
  Google Scholar
• 51. Hybertson B.M., Gao B., Bose S.K., McCord J.M.: Oxidative stressin health and disease: The therapeutic potential of Nrf2 activation.Mol. Aspects Med., 2011; 32: 234–246
  Google Scholar
• 52. Ingraham B.A., Bragdon B., Nohe A.: Molecular basis of the potentialof vitamin D to prevent cancer. Curr. Med. Res. Opin., 2008; 24: 139–149
  Google Scholar
• 53. James S.Y., Mackay A.G., Colston K.W.: Effects of 1,25 dihydroxyvitaminD3 and its analogues on induction of apoptosis in breastcancer cells. J. Steroid Biochem. Mol. Biol., 1996; 58: 395–401
  Google Scholar
• 54. Janjetovic Z., Brozyna A.A., Tuckey R.C., Kim T.K., Nguyen M.N.,Jozwicki W., Pfeffer S.R., Pfeffer L.M., Slominski A.T.: High basal NF-κB activity in nonpigmented melanoma cells is associated with anenhanced sensitivity to vitamin D3 derivatives. Br. J. Cancer, 2011;105: 1874–1884
  Google Scholar
• 55. Jensen S.S., Madsen M.W., Lukas J., Binderup L., Bartek J.: Inhibitoryeffects of 1α,25-dihydroxyvitamin D3 on the G1-S phase-controllingmachinery. Mol. Endocrinol., 2001; 15: 1370–1380
  Google Scholar
• 56. Jiang F., Bao J., Li P., Nicosia S.V., Bai W.: Induction of ovarian cancercell apoptosis by 1,25-dihydroxyvitamin D3 through the down–regulation of telomerase. J. Biol. Chem., 2004; 279: 53213–53221
  Google Scholar
• 57. Jóźwicki W., Brożyna A., Siekiera J., Slominski A.: Expression ofvitamin D receptor (VDR) positively correlates with survival of urothelialbladder cancer patients. Int. J. Mol. Sci., 2015; 16: 24369–24386
  Google Scholar
• 58. Kizildag S., Ates H., Kizildag S.: Treatment of K562 cells with1,25-dihydroxyvitamin D3 induces distinct alterations in the expressionof apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann.Hematol., 2010; 89: 1–7
  Google Scholar
• 59. Köstner K., Denzer N., Müller C.S., Klein R., Tilgen W., ReichrathJ.: The relevance of vitamin D receptor (VDR) gene polymorphismsfor cancer: A review of the literature. Anticancer Res., 2009;29: 3511–3536
  Google Scholar
• 60. Kovalenko P.L., Zhang Z., Cui M., Clinton S.K., Fleet J.C.: 1,25dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostateepithelial cell line, RWPE1. BMC Genomics, 2010; 11: 26–40
  Google Scholar
• 61. Krishnan A. V., Feldman D.: Molecular pathways mediating the anti–inflammatory effects of calcitriol: Implications for prostate cancer chemopreventionand treatment. Endocr. Relat. Cancer, 2010; 17: R19–R38
  Google Scholar
• 62. Krishnan A. V., Moreno J., Nonn L., Malloy P., Swami S., PengL., Peehl D.M., Feldman D.: Novel pathways that contribute to theanti-proliferative and chemopreventive activities of calcitriol inprostate cancer. J. Steroid Biochem. Mol. Biol., 2007; 103: 694–702
  Google Scholar
• 63. Lai Y.H., Fang T.C.: The pleiotropic effect of vitamin D. ISRN Nephrol.,2013; 2013: 898125
  Google Scholar
• 64. Lambert J.R., Kelly J.A., Shim M., Huffer W.E., Nordeen S.K., BaekS.J., Eling T.E., Lucia M.S.: Prostate derived factor in human prostatecancer cells: Gene induction by vitamin D via a p53-dependentmechanism and inhibition of prostate cancer cell growth. J. Cell.Physiol., 2006; 208: 566–574
  Google Scholar
• 65. Larriba M.J., González-Sancho J.M., Barbáchano A., Niell N.,Ferrer-Mayorga G., Muñoz A.: Vitamin D is a multilevel repressor ofWnt/β-catenin signaling in cancer cells. Cancers, 2013; 5: 1242–1260
  Google Scholar
• 66. Larriba M.J., González-Sancho J.M., Bonilla F., Muñoz A.: Interactionof vitamin D with membrane-based signaling pathways. Front.Physiol., 2014; 5: 60–70
  Google Scholar
• 67. Lehmann B., Meurer M.: Vitamin D metabolism. Dermatol. Ther.,2010; 23: 2–12
  Google Scholar
• 68. Li P., Li C., Zhao X., Zhang X., Nicosia S. V., Bai W.: p27Kip1 Stabilizationand G1 arrest by 1,25-dihydroxyvitamin D3 in ovarian cancercells mediated through down-regulation of cyclin E/cyclin-dependentkinase 2 and Skp1-cullin-F-box protein/Skp2 ubiquitin ligase.J. Biol. Chem., 2004; 279: 25260–25267
  Google Scholar
• 69. Li Z., Jia Z., Gao Y., Xie D., Wei D., Cui J., Mishra L., Huang S.,Zhang Y., Xie K.: Activation of vitamin D receptor signaling downregulatesthe expression of nuclear FOXM1 protein and suppressespancreatic cancer cell stemness. Clin. Cancer Res., 2015; 21: 844–853
  Google Scholar
• 70. Lieberman D.A. Prindiville S., Weiss D.G., Willett W.: Risk factorsfor advanced colonic neoplasia and hyperplastic polyps in asymptomaticindividuals. JAMA, 2003; 290: 2959–2967
  Google Scholar
• 71. Liu M., Lee M.H., Cohen M., Bommakanti M., Freedman L.P.:Transcriptional activation of the Cdk inhibitor p21 by vitamin D3leads to the induced differentiation of the myelomonocytic cell lineU937. Genes Dev., 1996; 10: 142–153
  Google Scholar
• 72. Liu Y., Wang X., Sun X., Lu S., Liu S.: Vitamin intake and pancreaticcancer risk reduction: A meta-analysis of observational studies.Medicine, 2018; 97: e0114–e0121
  Google Scholar
• 73. Ma Y., Hu Q., Luo W., Pratt R.N., Glenn S.T., Liu S., Trump D.L.,Johnson C.S.: 1α,25(OH)2D3 differentially regulates miRNA expressionin human bladder cancer cells. J. Steroid Biochem. Mol. Biol.,2015; 148: 166–171
  Google Scholar
• 74. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B., Canfield A.E.:1α,25-Dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo.Circ. Res., 2000; 87: 214–220
  Google Scholar
• 75. Moreno J., Krishnan A. V., Swami S., Nonn L., Peehl D.M., FeldmanD.: Regulation of prostaglandin metabolism by calcitriol attenuatesgrowth stimulation in prostate cancer cells. Cancer Res.,2005; 65: 7917–7925
  Google Scholar
• 76. Muto A., Kizaki M., Yamato K., Kawai Y., Kamata-Matsushita M.,Ueno H., Ohguchi M., Nishihara T., Koeffler H.P., Ikeda Y.: 1,25-DihydroxyvitaminD3 induces differentiation of a retinoic acid-resistantacute promyelocytic leukemia cell line (UF-1) associatedwith expression of p21 WAF1/CIP1 and p27 KIP1. Blood, 1999; 93: 2225–2233
  Google Scholar
• 77. Nakagawa K., Kawaura A., Kato S., Takeda E., Okano T.: 1α,25-Dihydroxyvitamin D3 is a preventive factor in the metastasis of lungcancer. Carcinogenesis, 2005; 26: 429–440
  Google Scholar
• 78. Noyola-Martínez N., Díaz L., Avila E., Halhali A., Larrea F., BarreraD.: Calcitriol downregulates TNF-α and IL-6 expression in culturedplacental cells from preeclamptic women. Cytokine, 2013;61: 245–250
  Google Scholar
• 79. Pálmer H.G., González-Sancho J.M., Espada J., Berciano M.T.,Puig I., Baulida J., Quintanilla M., Cano A., de Herreros A.G., LafargaM., Muñoz A.: Vitamin D3 promotes the differentiation of coloncarcinoma cells by the induction of E-cadherin and the inhibitionof β-catenin signaling. J. Cell Biol., 2001; 154: 369–387
  Google Scholar
• 80. Pálmer H.G., Larriba M.J., García J.M., Ordóñez-Morán P., PeñaC., Peiró S., Puig I., Rodríguez R., De La Fuente R., Bernad A., PollánM., Bonilla F., Gamallo C., García De Herreros A., Muñoz A.: The transcriptionfactor SNAIL represses vitamin D receptor expression andresponsiveness in human colon cancer. Nat. Med., 2004; 10: 917–919
  Google Scholar
• 81. Pálmer H.G., Sánchez-carbayo M., Ordóñez-morán P., LarribaM.J., Cordon-Cardo C., Munoz A.: Genetic signatures of differentiationinduced by 1α,25-dihydroxyvitamin D3 in human colon cancercells. Cancer Res., 2003; 63: 7799–7806
  Google Scholar
• 82. Peehl D.M., Shinghal R., Nonn L., Seto E., Krishnan A. V., BrooksJ.D., Feldman D.: Molecular activity of 1,25-dihydroxyvitaminD3 in primary cultures of human prostatic epithelial cells revealedby cDNA microarray analysis. J. Steroid Biochem. Mol. Biol., 2004;92: 131–141
  Google Scholar
• 83. Prosser D.E., Jones G.: Enzymes involved in the activation andinactivation of vitamin D. Trends Biochem. Sci., 2004; 29: 664–673
  Google Scholar
• 84. Prüfer K., Racz A., Lin G.C., Barsony J.: Dimerization with retinoidX receptors promotes nuclear localization and subnuclear targetingof vitamin D receptors. J. Biol. Chem., 2000; 275: 41114–41123
  Google Scholar
• 85. Reichrath J., Lehmann B., Carlberg C., Varani J., Zouboulis C.C.:Vitamins as hormones. Horm. Metab. Res., 2007; 39: 71–84
  Google Scholar
• 86. Rohan J.N., Weigel N.L.: 1α,25-Dihydroxyvitamin D3 reducesc-myc expression, inhibiting proliferation and causing G1 accumulationin C4-2 prostate cancer cells. Endocrinology, 2009; 150:2046–2054
  Google Scholar
• 87. Saramäki A., Banwell C.M., Campbell M.J., Carlberg C.: Regulationof the human p21waf1/cip1 gene promoter via multiple binding sites forp53 and the vitamin D3 receptor. Nucleic Acids Res., 2006; 34: 543–554
  Google Scholar
• 88. Sawada N., Inoue M., Iwasaki M., Yamaji T., Shimazu T., SasazukiS., Tsugane S.: Plasma 25-hydroxy vitamin D and subsequent prostatecancer risk in a nested case-control study in Japan: The JPHCstudy. Eur. J. Clin. Nutr., 2017; 71: 132–136
  Google Scholar
• 89. Schwartz G.G., Eads D., Rao A., Cramer S.D., Willingham M.C.,Chen T.C., Jamieson D.P., Wang L., Burnstein K.L., Holick M.F., KoumenisC.: Pancreatic cancer cells express 25-hydroxyvitamin D-1α-hydroxylase and their proliferation is inhibited by the prohormone25-hydroxyvitamin D3. Carcinogenesis, 2004; 25: 1015–1026
  Google Scholar
• 90. Schwartz G.G., Whitlatch L.W., Chen T.C., Lokeshwar B.L., Holick M.F.:Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitaminD3. Cancer Epidemiol. Biomarkers Prev., 1998; 7: 391–395
  Google Scholar
• 91. Scott M.G., Gronowski A.M., Reid I.R., Holick M.F., Thadhani R.,Phinney K.: Vitamin D: The more we know, the less we know. Clin.Chem., 2015; 61: 462–465
  Google Scholar
• 92. Shabahang M., Buras R.R., Davoodi F., Schumaker L.M., NautaR.J., Evans S.R.: 1,25-Dihydroxyvitamin D3 receptor as a marker ofhuman colon carcinoma cell line differentiation and growth inhibition.Cancer Res., 1993; 53: 3712–3718
  Google Scholar
• 93. Sherr C.J., Roberts J.M.: Inhibitors of mammalian G1 cyclin-dependentkinases. Genes Dev., 1995; 9: 1149–1163
  Google Scholar
• 94. Simboli-Campbell M., Narvaez C.J., Tenniswood M., Welsh J.:1,25-Dihydroxyvitamin D3 induces morphological and biochemicalmarkers of apoptosis in MCF-7 breast cancer cells. J. Steroid Biochem.Mol. Biol., 1996; 58: 367–376
  Google Scholar
• 95. Skowronski R.J., Peehl D.M., Feldman D.: Vitamin D and prostatecancer: 1,25 dihydroxyvitamin D3 receptors and actions in humanprostate cancer cell lines. Endocrinology, 1993; 132: 1952–1960
  Google Scholar
• 96. Slominski A.T., Brozyna A., Jozwicki W., Tuckey R.C.: Vitamin Das an adjuvant in melanoma therapy. Melanoma Manag., 2015; 2: 1–4
  Google Scholar
• 97. Slominski A.T., Brożyna A.A., Zmijewski M.A., Jóźwicki W., JettenA.M., Mason R.S., Tuckey R.C., Elmets C.A.: Vitamin D signaling andmelanoma: role of vitamin D and its receptors in melanoma progressionand management. Lab. Investig., 2017; 97: 706–724
  Google Scholar
• 98. Slominski A.T., Kim T.K., Hobrath J. V., Oak A.S., Tang E.K., TieuE.W., Li W., Tuckey R.C., Jetten A.M.: Endogenously produced nonclassicalvitamin D hydroxy-metabolites act as “biased” agonists onVDR and inverse agonists on RORα and RORγ. J. Steroid Biochem.Mol. Biol., 2017; 173: 42–56
  Google Scholar
• 99. Slominski A.T., Kim T.K., Li W., Postlethwaite A., Tieu E.W., TangE.K., Tuckey R.C.: Detection of novel CYP11A1-derived secosteroidsin the human epidermis and serum and pig adrenal gland. Sci. Rep.,2015; 5: 14875–14886
  Google Scholar
• 100. Slominski A.T., Kim T.K., Shehabi H.Z., Semak I., Tang E.K.,Nguyen M.N., Benson H.A., Korik E., Janjetovic Z., Chen J., Yates C.R.,Postlethwaite A., Li W., Tuckey R.C.: In vivo evidence for a novel pathwayof vitamin D3 metabolism initiated by P450scc and modified byCYP27B1. FASEB J., 2012; 26: 3901–3915
  Google Scholar
• 101. Slominski A.T., Kim T.K., Takeda Y., Janjetovic Z., Broz˙yna A.A.,Skobowiat C., Wang J., Postlethwaite A., Li W., Tuckey R.C., JettenA.M.: RORα and ROR γ are expressed in human skin and serve as receptorsfor endogenously produced noncalcemic 20-hydroxy- and20,23-dihydroxyvitamin D. FASEB J., 2014; 28: 2775–2789
  Google Scholar
• 102. Slominski A.T., Li W., Kim T.K., Semak I., Wang J., Zjawiony J.K.,Tuckey R.C.: Novel activities of CYP11A1 and their potential physiologicalsignificance. J. Steroid Biochem. Mol. Biol., 2015; 151: 25–37
  Google Scholar
• 103. So J.Y., Smolarek A.K., Salerno D.M., Maehr H., Uskokovic M.,Liu F., Suh N.: Targeting CD44-STAT3 signaling by gemini vitaminD analog leads to inhibition of invasion in basal-like breast cancer.PLoS One, 2013; 8: e54020–e54029
  Google Scholar
• 104. Sone T., Kerner S., Pike J.W.: Vitamin D receptor interactionwith specific DNA. Association as a 1,25-dihydroxyvitamin D3-modulatedheterodimer. J. Biol. Chem., 1991; 266: 23296–23305
  Google Scholar
• 105. Stolzenberg-Solomon R.Z., Vieth R., Azad A., Pietinen P., TaylorP.R., Virtamo J., Albanes D.: A prospective nested case-controlstudy of vitamin D status and pancreatic cancer risk in male smokers.Cancer Res., 2006; 66: 10213–10219
  Google Scholar
• 106. Szyszka P., Zmijewski M.A., Slominski A.T.: New vitamin D analogsas potential therapeutics in melanoma. Expert Rev. AnticancerTher., 2012; 12: 585–599
  Google Scholar
• 107. Tang E.K., Chen J., Janjetovic Z., Tieu E.W., Slominski A.T., LiW., Tuckey R.C.: Hydroxylation of CYP11A1-derived products of vitaminD3 metabolism by human and Mouse CYP27B1. Drug Metab.Dispos., 2013; 41: 1112–1124
  Google Scholar
• 108. Tavera-Mendoza L., Wang T.T., Lallemant B., Zhang R., Nagai Y.,Bourdeau V., Ramirez-Calderon M., Desbarats J., Mader S., White J.H.:Convergence of vitamin D and retinoic acid signalling at a commonhormone response element. EMBO Rep., 2006; 7: 180–185
  Google Scholar
• 109. Tieu E.W., Li W., Chen J., Kim T.K., Ma D., Slominski A.T., TuckeyR.C.: Metabolism of 20-hydroxyvitamin D3 and 20,23-dihydroxyvitaminD3 by rat and human CYP24A1. J. Steroid Biochem. Mol. Biol.,2015; 149: 153–165
  Google Scholar
• 110. Toner C.D., Davis C.D., Milner J.A.: The vitamin D and cancerconundrum: Aiming at a moving target. J. Am. Diet. Assoc., 2010;110: 1492–1500
  Google Scholar
• 111. Tong W.M., Hofer H., Ellinger A., Peterlik M., Cross H.S.: Mechanismof antimitogenic action of vitamin D in human colon carcinomacells: relevance for suppression of epidermal growth factor-stimulatedcell growth. Oncol. Res., 1999; 11: 77–84
  Google Scholar
• 112. Townsend K., Banwell C.M., Guy M., Colston K.W., Mansi J.L.,Stewart P.M., Campbell M.J., Hewison M.: Autocrine metabolism ofvitamin D in normal and malignant breast tissue. Clin. Cancer Res.,2005; 11: 3579–3586
  Google Scholar
• 113. Wacker M., Holick M.F.: Sunlight and vitamin D. A global perspectivefor health. Dermatoendocrinol., 2013; 5: 51–108
  Google Scholar
• 114. Wagner N., Wagner K.D., Schley G., Badiali L., Theres H., ScholzH.: 1,25-Dihydroxyvitamin D3-induced apoptosis of retinoblastomacells is associated with reciprocal changes of Bcl-2 and bax. Exp.Eye Res., 2003; 77: 1–9
  Google Scholar
• 115. Wang Q.M., Jones J.B., Studzinski G.P.: Cyclin-dependent kinaseinhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitaminD3 in HL60 cells. Cancer Res., 1996; 56: 264–267
  Google Scholar
• 116. Wasiewicz T., Szyszka P., Cichorek M., Janjetovic Z., Tuckey R.,Slominski A., Zmijewski M.: Antitumor effects of vitamin D analogson hamster and mouse melanoma cell lines in relation to melaninpigmentation. Int. J. Mol. Sci., 2015; 16: 6645–6667
  Google Scholar
• 117. Wierzbicka J., Piotrowska A., Żmijewski M.A.: The renaissanceof vitamin D. Acta Biochim. Pol., 2014; 61: 679–686
  Google Scholar
• 118. Yamada O., Ozaki K., Nakatake M., Akiyama M., Kawauchi K.,Matsuoka R.: Multistep regulation of telomerase during differentiationof HL60 cells. J. Leukoc. Biol., 2008; 83: 1240–1248
  Google Scholar
• 119. Ylikomi T., Laaksi I., Lou Y.R., Martikainen P., Miettinen S., PennanenP., Purmonen S., Syvälä H., Vienonen A., Tuohimaam P.: Antiproliferativeaction of vitamin D. Vitam. Horm., 2002; 64: 357–406
  Google Scholar
• 120. Zhang X., Nicosia S.V., Bai W.: Vitamin D receptor is a noveldrug target for ovarian cancer treatment. Curr. Cancer Drug Targets,2006; 6: 229–244
  Google Scholar

Full text